NEW YORK CITY, NY / ACCESS Newswire / February 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of ...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pliant Therapeutics, Inc. ("Pliant" or "the Company") (NASDAQ: ...
Oppenheimer analysts downgraded Pliant Therapeutics stock from Outperform to Perform, following a significant development ...
Pliant Therapeutics (PLRX) stock jumped 21% Thursday after the company issued an update for a Phase 2b clinical study of ...
In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...
Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...
Pliant Therapeutics, Inc. (NASDAQ:PLRX) stock is trading lower on Monday. On Friday, during after-hours trading, Pliant ...
H.C. Wainwright downgraded Pliant Therapeutics (NASDAQ:PLRX) stock from Buy to Neutral following concerns about the safety of ...
The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...
Pliant Therapeutics shares were up 23% to $3.34 after the company said an independent Data Safety Monitoring Board is allowing it to begin the assembly of an outside expert panel to review unblinded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results